Abstract
Lentiviral vectors pseudotyped with G glycoprotein from vesicular stomatitis virus (VSV-G) and baculovirus gp64 are inactivated by human complement. The extent of vector inactivation in serum from individual donors was examined and results showed wide donor-dependent variation in complement sensitivity for VSV-G-pseudotyped lentivectors. Amphotropic envelope (Ampho)-pseudotyped vectors were generally resistant to serum from all donors, while gp64-pseudotyped vectors were inactivated but showed less donor-to-donor variation than VSV-G. In animal sera, the vectors were mostly resistant to inactivation by rodent complement, whereas canine complement caused a moderate reduction in titer. In a novel advance for the lentiviral vector system, human complement–resistant-pseudotyped lentivector particles were produced through incorporation of complement regulatory proteins (CRPs). Decay accelerating factor (DAF)/CD55 provided the most effective protection using this method, while membrane cofactor protein (MCP)/CD46 showed donor-dependent protection and CD59 provided little or no protection against complement inactivation. Unlike previous approaches using CRPs to produce complement–resistant viral vectors, CRP-containing lentivectors particles were generated for this study without engineering the CRP molecules. Thus, through overexpression of native DAF/CD55 in the viral producer cell, an easy method was developed for generation of lentiviral vectors that are almost completely resistant to inactivation by human complement. Production of complement–resistant lentiviral particles is a critical step toward use of these vectors for in vivo gene therapy applications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Emi N, Friedmann T, Yee JK . Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991; 65: 1202–1207.
Burns JC et al. Vesicular stomatitis virus G protein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033–8037.
Schauber CA et al. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restricted against hematopoietic cell types in vitro. Gene Therapy 2004; 11: 266–275.
Kumar M, Bradow BP, Zimmerberg J . Large-scale production of pseudotyped lentiviral vectors using baculovirus gp64. Hum Gene Ther 2003; 14: 67–77.
Yee JK, Friedmann T, Burns JC . Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 1994; 43: 99–112.
DePolo NJ et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2: 218–222.
Takeuchi Y, Porter C, Strahan K . Sensitization of cells and retroviruses to human serum by alpha(1–3)galactosyltransferase. Nature 1996; 379: 85–88.
Takeuchi Y, Liong SH, Bieniasz PD . Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. J Virol 1997; 71: 6174–6178.
Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cells. J Virol 1994; 68: 8001–8007.
Pensiero MN, Wysocki CA, Nader K, Kikuchi GE . Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7: 1095–1101.
Rigg RJ et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved stability. Virology 1996; 218: 290–295.
Rollins SA, Birks CW, Squinto SP, Rother RP . Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther 1996; 7: 619–626.
Sandrin V et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100: 823–832.
Kost TA, Condreay JP . Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 2002; 20: 173–180.
Hofmann C, Strauss M . Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Therapy 1998; 5: 531–536.
Huser A, Rudolph M, Hofmann C . Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol 2001; 19: 451–455.
Marchal I, Jarvis DL, Cacan R, Verbert A . Glycoproteins of insect cells: sialylated or not? Biol Chem 2001; 382: 151–159.
Beebe DP, Cooper NR . Neutralization of vesicular stomatitis virus (VSV) by human complement required a natural IgM antibody present in human serum. J Immunol 1981; 126: 1562–1568.
Welsh RMJ, O'Donnell CL, Reed DJ, Rother RP . Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998; 72: 4650–4656.
Cooper NR, Jensen FC, Welsh RMJ, Oldstone MB . Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976; 144: 970–984.
Miyao Y et al. FUT-175, a synthetic inhibitor of the complement pathway protects against the inactivation of infectious retroviruses by human serum. Hum Gene Ther 1997; 8: 1575–1583.
Bartholomew RM, Esser AF . Mechanism of antibody-independent inactivation of the first component of complement (C1) on retrovirus membranes. Biochemistry 1980; 19: 2846–2853.
Uthaisangsook S et al. Innate immunity and its role against infections. Ann Allergy Asthma Immunol 2002; 88: 253–254.
Fujita T et al. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166: 1221–1228.
Oglesby TJ et al. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 1992; 175: 1547–1551.
Rollins SA, Sims PJ . The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478–3483.
Townsend K et al. Adaptation of a lentiviral vector producer cell line to reduced-serum, suspension culture for large-scale production. Mol Ther 2004; 9 (Suppl. 1) Abstract #82, S33.
Spitzer D, Hauser H, Wirth D . Complement-protected amphotropic retroviruses from murine packaging cells. Hum Gene Ther 1999; 10: 1893–1902.
Ochsenbein AF et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286: 2156–2159.
Saifuddin M et al. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997; 78: 1907–1911.
Montefiori DC et al. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994; 205: 82–92.
Marschang P, Sodroski J, Wurzner R, Dierich MP . Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995; 25: 285–290.
Saifuddin M et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995; 182: 501–509.
Dull T et al. A third generation lentiviral vector with a conditional packaging system. J Virol 1998; 72: 8463–8471.
Follenzi A et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243–260.
Finer MH et al. Kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83: 43–50.
Acknowledgements
We thank Sandy Sanchez for DNA sequencing and oligo synthesis as well as the Cell Genesys animal facility for mouse and rat serum. We are also grateful to Carol Lin for her efforts in CD55 Western blotting. Special thanks to members of the lentiviral vector group for helpful discussions and critical reading of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schauber-Plewa, C., Simmons, A., Tuerk, M. et al. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther 12, 238–245 (2005). https://doi.org/10.1038/sj.gt.3302399
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302399
Keywords
This article is cited by
-
The stability of envelope-pseudotyped lentiviral vectors
Gene Therapy (2021)
-
A simple strategy for retargeting lentiviral vectors to desired cell types via a disulfide-bond-forming protein-peptide pair
Scientific Reports (2018)
-
Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59
Molecular Biotechnology (2016)
-
Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors
Gene Therapy (2013)
-
A MicroRNA-regulated and GP64-pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in a Murine Model of Hemophilia A
Molecular Therapy (2011)